Itraconazole Eg

Itraconazole, the active ingredient in Itraconazole Eg, is a Triazole antifungal presented as a unknown/unknown for oral use. It treats a range of fungal infections in both adult and pediatric patients as prescribed.

GNH USA supplies Itraconazole Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is a triazole antifungal that interferes with fungal cell membrane synthesis, making it effective for several mycotic conditions. - Dermatophyte infections: effective in treating skin fungal infections caused by dermatophytes. - Onychomycosis: promotes clearance of fungal nail disease. - Blastomycosis: used for systemic infection caused by Blastomyces dermatitidis. - Histoplasmosis: indicated for disseminated histoplasma infection. - Coccidioidomycosis: treats severe pulmonary or disseminated disease. - Aspergillosis: employed in chronic or invasive aspergillus infections.

Adverse reactions may occur with itraconazole therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional expulsion of stomach contents. - Abdominal pain: discomfort or cramps in the stomach area. - Headache: transient head pain. - Rash: skin redness or itching. - Taste alteration: dysgeusia or loss of taste.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of congestive heart failure. - Visual disturbances: blurred vision or photophobia. - Severe allergic reactions: anaphylaxis or angioedema. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Itraconazole requires careful monitoring and specific safety measures. - Liver function monitoring: assess hepatic enzymes before and during therapy. - Drug interaction assessment: review concomitant medications for potential interactions. - Pregnancy safety: avoid use in pregnancy unless benefits outweigh risks (Category D). - Hepatic impairment dose adjustment: modify dose in patients with liver disease. - Cardiac caution: use cautiously in patients with existing heart failure. - Store at below 25°C: keep in the original pack, protect from moisture.

Itraconazole can affect the metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Rifampin: strong enzyme inducer that reduces itraconazole levels. - St. John’s wort: herbal inducer leading to decreased efficacy. - Ketoconazole: concurrent use may increase toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Statins (e.g., simvastatin): increased risk of myopathy; dose adjustment may be needed. - Calcium channel blockers: may require dose modification. - Oral contraceptives: efficacy may be reduced, consider alternative contraception.